This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Pivotal Trial Results
Post-Hoc Analysis Results
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Some patients saw1-3:
Some patients saw1-3:
CIBINQO is an oral, once-daily treatment option1:
Studied in 3582 patients 12 and older with AD across multiple clinical trials4
CIBINQO has a BOXED WARNING for serious infections, mortality, malignancy, MACE, and thrombosis.1
Explore commercial coverage for CIBINQO
Help eligible, commercially insured patients gain access to copay savings*
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2023 Pfizer Inc. All rights reserved.